Literature DB >> 16988660

Gene therapy: is IL2RG oncogenic in T-cell development?

Karin Pike-Overzet1, Dick de Ridder, Floor Weerkamp, Miranda R M Baert, Monique M Verstegen, Martijn H Brugman, Steven J Howe, Marcel J T Reinders, Adrian J Thrasher, Gerard Wagemaker, Jacques J M van Dongen, Frank J T Staal.   

Abstract

The gene IL2RG encodes the gamma-chain of the interleukin-2 receptor and is mutated in patients with X-linked severe combined immune deficiency (X-SCID). Woods et al. report the development of thymus tumours in a mouse model of X-SCID after correction by lentiviral overexpression of IL2RG and claim that these were caused by IL2RG itself. Here we find that retroviral overexpression of IL2RG in human CD34+ cells has no effect on T-cell development, whereas overexpression of the T-cell acute lymphoblastic leukaemia (T-ALL) oncogene LMO2 leads to severe abnormalities. Retroviral expression of IL2RG may therefore not be directly oncogenic--rather, the restoration of normal signalling by the interleukin-7 receptor to X-SCID precursor cells allows progression of T-cell development to stages that are permissive for the pro-leukaemic effects of ectopic LMO2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988660     DOI: 10.1038/nature05218

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  21 in total

Review 1.  Integration site selection by retroviral vectors: molecular mechanism and clinical consequences.

Authors:  René Daniel; Johanna A Smith
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

2.  Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.

Authors:  Paritha I Arumugam; Tomoyasu Higashimoto; Fabrizia Urbinati; Ute Modlich; Shawna Nestheide; Ping Xia; Catherine Fox; Andrea Corsinotti; Christopher Baum; Punam Malik
Journal:  Mol Ther       Date:  2009-08-25       Impact factor: 11.454

Review 3.  Gene Therapy for the Treatment of Primary Immune Deficiencies.

Authors:  Caroline Y Kuo; Donald B Kohn
Journal:  Curr Allergy Asthma Rep       Date:  2016-05       Impact factor: 4.806

Review 4.  Engineering humanized mice for improved hematopoietic reconstitution.

Authors:  Adam C Drake; Qingfeng Chen; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2012-03-19       Impact factor: 11.530

Review 5.  Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders.

Authors:  Gerard Wagemaker
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

Review 6.  Novel insights into the development of T-cell acute lymphoblastic leukemia.

Authors:  Frank J T Staal; Jacques J M van Dongen; Anton W Langerak
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

7.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

Authors:  Salima Hacein-Bey-Abina; Alexandrine Garrigue; Gary P Wang; Jean Soulier; Annick Lim; Estelle Morillon; Emmanuelle Clappier; Laure Caccavelli; Eric Delabesse; Kheira Beldjord; Vahid Asnafi; Elizabeth MacIntyre; Liliane Dal Cortivo; Isabelle Radford; Nicole Brousse; François Sigaux; Despina Moshous; Julia Hauer; Arndt Borkhardt; Bernd H Belohradsky; Uwe Wintergerst; Maria C Velez; Lily Leiva; Ricardo Sorensen; Nicolas Wulffraat; Stéphane Blanche; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 8.  Recent advances in gene therapy for severe congenital immunodeficiency diseases.

Authors:  Robert Sokolic; Chimene Kesserwan; Fabio Candotti
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

9.  Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.

Authors:  Takafumi Hiramoto; Li B Li; Sarah E Funk; Roli K Hirata; David W Russell
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

Review 10.  Thymocyte self-renewal and oncogenic risk in immunodeficient mouse models: relevance for human gene therapy clinical trials targeting haematopoietic stem cell populations?

Authors:  Samantha L Ginn; Matthew P McCormack; Ian E Alexander
Journal:  Mamm Genome       Date:  2018-09-04       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.